Annual report pursuant to Section 13 and 15(d)

Segments

v3.10.0.1
Segments
12 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Segments Segments
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations we acquired through the acquisition of BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the years ended December 31,
(In thousands)
2018
 
2017
 
2016
Revenue from services:
 
 
 
 
 
Pharmaceutical
$

 
$

 
$

Diagnostics
813,248

 
782,710

 
928,572

Corporate

 

 

 
$
813,248

 
$
782,710

 
$
928,572

Revenue from products:
 
 
 
 
 
Pharmaceutical
$
107,112

 
$
107,759

 
$
83,467

Diagnostics

 

 

Corporate

 

 

 
$
107,112

 
$
107,759

 
$
83,467

Revenue from transfer of intellectual property and other:
 
 
 
 
 
Pharmaceutical
$
69,906

 
$
75,537

 
$
105,455

Diagnostics

 

 

Corporate

 

 

 
$
69,906

 
$
75,537

 
$
105,455

Operating loss:
 
 
 
 
 
Pharmaceutical
$
(82,641
)
 
$
(84,287
)
 
$
(33,117
)
Diagnostics
(44,942
)
 
(136,540
)
 
(3,394
)
Corporate
(43,614
)
 
(55,615
)
 
(60,040
)
 
$
(171,197
)
 
$
(276,442
)
 
$
(96,551
)
Depreciation and amortization:
 
 
 
 
 
Pharmaceutical
$
28,007

 
$
27,513

 
$
18,254

Diagnostics
69,246

 
74,442

 
78,233

Corporate
91

 
138

 
89

 
$
97,344

 
$
102,093

 
$
96,576

Income (loss) from investment in investees:
 
 
 
 
 
Pharmaceutical
$
(10,822
)
 
$
(12,646
)
 
$
(7,665
)
Diagnostics
(3,675
)
 
(1,825
)
 
13

Corporate

 

 

 
$
(14,497
)
 
$
(14,471
)
 
$
(7,652
)
Revenues:
 
 
 
 
 
United States
$
837,509

 
$
803,853

 
$
933,498

Ireland
78,102

 
80,905

 
114,509

Chile
41,216

 
44,286

 
35,364

Spain
18,195

 
18,285

 
15,812

Israel
9,479

 
13,951

 
15,317

Mexico
5,598

 
4,605

 
2,988

Other
167


121

 
6

 
$
990,266

 
$
966,006

 
$
1,117,494


(In thousands)
December 31,
2018
 
December 31,
2017
Assets:
 
 
 
Pharmaceutical
$
1,236,499

 
$
1,282,564

Diagnostics
1,162,160

 
1,241,388

Corporate
52,413

 
66,004

 
$
2,451,072

 
$
2,589,956

Goodwill:
 
 
 
Pharmaceutical
$
247,407

 
$
264,313

Diagnostics
452,786

 
452,786

Corporate

 

 
$
700,193

 
$
717,099


No customer represented more than 10% of our total consolidated revenue during the years ended December 31, 2018, 2017 and 2016. As of December 31, 2018 and 2017, no customer represented more than 10% of our accounts receivable balance.
The following table reconciles our Property, plant and equipment, net between U.S. and foreign jurisdictions: 
(In thousands)
December 31, 2018
 
December 31, 2017
PP&E:
 
 
 
U.S.
$
76,907

 
$
89,114

Foreign
67,767

 
57,443

Total
$
144,674

 
$
146,557